Y481 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñ°æ±¸¸¶ÃëÁ¦ | Parenteral anesthetics causing adverse effects in therapeutic use |
 |
Y481 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ŸÀÌ¿À¹ÙºñÃò·¹ÀÌÆ® | Thiobarbiturate causing adverse effects in therapeutic use |
 |
Y482 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Àü½Å¸¶ÃëÁ¦ | Other and unspecified general anesthetics causing adverse effects in therapeutic use |
 |
Y483 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼Ò¸¶ÃëÁ¦ | Local anesthetic causing adverse effects in therapeutic use |
 |
Y484 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ ¸¶ÃëÁ¦ | Anesthetics, unspecified causing adverse effects in therapeutic use |
 |
Y485 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢Á¾ Ä¡·á¿ë°¡½º | Therapeutic gases causing adverse effects in therapeutic use |
 |
Y49 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Á¤½ÅÀÛ¿ë¾à¹° | Psychotropic drugs, NEC causing adverse effects in therapeutic use |
 |
Y490 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æ®¸®»çÀÌŬ¸¯ ¹× Åׯ®¶ó»çÀÌŬ¸¯ Ç׿ì¿ïÁ¦ | Tricyclic and tetracyclic antidepressants causing adverse effects in therapeutic use |
 |
Y491 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸ð³ë¾Æ¹Î-¿Á½Ãµ¥À̽º ¾ïÁ¦¼º Ç׿ì¿ïÁ¦ | Monoamine-oxidase-inhibitor antidepressants causing adverse effects in therapeutic use |
 |
Y492 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Ç׿ì¿ïÁ¦ | Other and unspecified antidepressants causing adverse effects in therapeutic use |
 |
Y493 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Æä³ëµð¾ÆÁø Ç×Á¤½Åº´ ¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ | Phenothiazine antipsychotics and neuroleptics causing adverse effects in therapeutic use |
 |
Y494 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎƼ·ÎÆä³í ¹× Áö¿Á»êƾ ½Å°æÀÌ¿ÏÁ¦ | Butyrophenone and thioxanthene neuroleptics causing adverse effects in therapeutic use |
 |
Y495 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ Ç×Á¤½Åº´¾àÁ¦ ¹× ½Å°æÀÌ¿ÏÁ¦ | Other antipsychotics and neuroleptics causing adverse effects in therapeutic use |
 |
Y496 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ȯ°¢Á¦ | Psychodysleptics [hallucinogens] causing adverse effects in therapeutic use |
 |
Y497 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ³²¿ëÀÇ ÀáÀ缺ÀÌ ÀÖ´Â Á¤½ÅÈïºÐÁ¦ | Psycostimulants with abuse potential causing adverse effects in therapeutic use |
 |
Y498 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±âŸ Á¤½ÅÀÛ¿ë¾à¹° | Other psychotropic drugs, NEC causing adverse effects in therapeutic use |
 |
Y499 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ó¼¼ºÒ¸íÀÇ Á¤½ÅÀÛ¿ë¾à¹° | Psychotropic drug, unspecified causing adverse effects in therapeutic use |
 |
Y50 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ÁßÃ߽Űæ°èÅë ÈïºÐÁ¦ | Central nervous system stimulants, NEC causing adverse effects in therapeutic use |
 |
Y500 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¢¼ºÁ¦ | Analeptics causing adverse effects in therapeutic use |
 |
Y501 | Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾ÆÆí¼ö¿ëü±æÇ×Á¦ | Opioid reactor antagonists causing adverse effects in therapeutic use |
 |